17.96
Schlusskurs vom Vortag:
$17.59
Offen:
$17.59
24-Stunden-Volumen:
160.47K
Relative Volume:
0.48
Marktkapitalisierung:
$577.59M
Einnahmen:
$4.12M
Nettoeinkommen (Verlust:
$-56.68M
KGV:
-3.2402
EPS:
-5.5429
Netto-Cashflow:
$-51.44M
1W Leistung:
+1.58%
1M Leistung:
-17.24%
6M Leistung:
-27.23%
1J Leistung:
-17.39%
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Vergleichen Sie DNTH mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
DNTH
Dianthus Therapeutics Inc
|
17.96 | 568.59M | 4.12M | -56.68M | -51.44M | -5.5429 |
![]()
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-20 | Eingeleitet | TD Cowen | Buy |
2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
2024-02-15 | Eingeleitet | Stifel | Buy |
2023-12-26 | Eingeleitet | Jefferies | Buy |
2023-11-22 | Eingeleitet | Wedbush | Outperform |
2023-10-30 | Eingeleitet | Guggenheim | Buy |
2023-09-28 | Eingeleitet | Raymond James | Outperform |
2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
2021-08-20 | Fortgesetzt | Goldman | Neutral |
2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-07-22 | Bestätigt | B. Riley Securities | Buy |
2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-06-15 | Eingeleitet | BTIG Research | Buy |
2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
2021-01-07 | Eingeleitet | Mizuho | Buy |
2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Millennium Management LLC Has $1.97 Million Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Millennium Management LLC - Defense World
BNP Paribas Financial Markets Makes New Investment in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.2%Time to Sell? - MarketBeat
Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $53.00 - MarketBeat
Deutsche Bank AG Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference - The Manila Times
Autoimmune Disease Biotech Dianthus Therapeutics CEO Takes Stage at Major Jefferies Conference - Stock Titan
Northern Trust Corp Acquires 42,923 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Woodline Partners LP - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Point72 Asset Management L.P. Reduces Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Vestal Point Capital LP - MarketBeat
Dianthus Therapeutics appoints new board member By Investing.com - Investing.com India
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors - citybiz
Dianthus Therapeutics appoints new board member - Investing.com Australia
Dianthus Therapeutics Announces Board Changes and Elections - TipRanks
Former Novartis-Acquired CEO Joins Dianthus Board Ahead of Critical Phase 2 Data - Stock Titan
Janus Henderson Group PLC Buys 136,314 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Buy Rating Affirmed for Dianthus Therapeutics: Promising Clinical Potential of DNTH103 in CIDP Treatment - TipRanks
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Raised by Octagon Capital Advisors LP - MarketBeat
Robert W. Baird Has Lowered Expectations for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
FY2025 EPS Estimates for DNTH Lowered by Cantor Fitzgerald - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Earns "Buy" Rating from HC Wainwright - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Bought by Price T Rowe Associates Inc. MD - Defense World
Wedbush Research Analysts Raise Earnings Estimates for DNTH - Defense World
HC Wainwright Issues Positive Forecast for DNTH Earnings - Defense World
Tower Research Capital LLC TRC Sells 944 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Robert W. Baird Issues Pessimistic Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World
HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.1% Following Analyst Downgrade - Defense World
DNTH: HC Wainwright & Co. Reiterates Buy Rating with $40 Target - GuruFocus
DNTH Stock Target Price Lowered by Analyst Baird | DNTH Stock Ne - GuruFocus
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views - Benzinga
Wedbush Adjusts Price Target on Dianthus Therapeutics to $34 From $36, Maintains Outperform Rating - marketscreener.com
Dianthus (DNTH) Target Price Adjusted Amid Q1 Pipeline Update | - GuruFocus
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results - The Manila Times
Dianthus Therapeutics Reports Increased R&D Expenses - TipRanks
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Lifted by Braidwell LP - MarketBeat
Avidity Partners Management LP Lowers Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):